Exelixis | EXEL - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Bayer EUR 3.53B 2.42B 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cytokinetics USD -181.23M 2.86M 2026-03
Eisai JPY -10.31B 30.35B 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Exelixis USD 251.34M 15.43M 2026-03
Genmab DKK 260M 199M 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 324.17M 59.7M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
MacroGenics USD -12.1M 30.74M 2025-12
Merck USD -1.88B 8.12B 2026-03
Moderna USD -1.39B 531M 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.24B 171M 2026-03
Pfizer USD 4.99B 340M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sanofi EUR 1.5B 2.29B 2025-12
Takeda JPY -13.62B 182.44B 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Xencor USD -77.86M 24.23M 2026-03